Evidence map›Paper›PMID 38973913›Full record

ArticleACS omega2024

Metronidazole Interaction with Cu

Federica Carnamucio, Claudia Foti, Nicola Micale, Natascha Van Pelt, An Matheeussen, Guy Caljon, Ottavia Giuffrè

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Comprehensive Speciation and Computational Study of CuMolecules (Basel, Switzerland) · 2025
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Federica CarnamucioDepartment of Pharmaceutics and Center for Pharmaceutical Engineering and Sciences, School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia 23284, United States.ORCID https://orcid.org/0000-0003-2218-953X
Claudia FotiDipartimento di Scienze Chimiche, Biologiche, Farmaceutiche ed Ambientali, Università di Messina, Viale F. Stagno d'Alcontres 31, 98166 Messina, Italy.ORCID https://orcid.org/0000-0003-2649-7660
Nicola MicaleDipartimento di Scienze Chimiche, Biologiche, Farmaceutiche ed Ambientali, Università di Messina, Viale F. Stagno d'Alcontres 31, 98166 Messina, Italy.ORCID https://orcid.org/0000-0002-9294-6033
Natascha Van PeltLaboratory of Microbiology, Parasitology and Hygiene (LMPH), Infla-Med Centre of Excellence, University of Antwerp, S7, Universiteitsplein 1, 2610 Wilrijk, Antwerp, Belgium.ORCID https://orcid.org/0000-0001-8922-7903
An MatheeussenLaboratory of Microbiology, Parasitology and Hygiene (LMPH), Infla-Med Centre of Excellence, University of Antwerp, S7, Universiteitsplein 1, 2610 Wilrijk, Antwerp, Belgium.
Guy CaljonLaboratory of Microbiology, Parasitology and Hygiene (LMPH), Infla-Med Centre of Excellence, University of Antwerp, S7, Universiteitsplein 1, 2610 Wilrijk, Antwerp, Belgium.ORCID https://orcid.org/0000-0002-4870-3202
Ottavia GiuffrèDipartimento di Scienze Chimiche, Biologiche, Farmaceutiche ed Ambientali, Università di Messina, Viale F. Stagno d'Alcontres 31, 98166 Messina, Italy.ORCID https://orcid.org/0000-0002-8486-8733

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metronidazole (2-methyl-5-nitro-1

Identifiers

PMID38973913
PMCPMC11223215

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.